FDA advisory panel to review research about mixing different COVID-19 vaccines
New research from the National Institutes of Health has found that mixing one company’s COVID-19 vaccine with another company’s can be safe and effective.
The findings are set to be presented to a Food and Drug Administration panel Friday.
The study also determined that those who got the Johnson & Johnson COVID-19 vaccine as a first shot had a stronger immune response when boosted with the Pfizer or Moderna vaccines.
Health care workers at vaccination sites across Long Island say they are already getting calls and walk-ups regarding the topic.
“They’re really interested to know about that third dose or that booster shot that they need,” says Amber Vitale, a nurse practitioner working in Elmont.
The data is being presented to the FDA panel as part of a series of meetings to consider requests from both Moderna and Johnson & Johnson to authorize booster doses of their vaccines.
Dr. Mundeep Kainth of Northwell Health says if the FDA approves their requests, it will help get more people vaccinated because some people have had problems finding certain vaccine brands locally.
“I think that will be a great way to sort of fill in the gaps of vaccination in our communities,” Kainth says.
Long Islanders seem to have mixed feelings about mixing vaccines.
“For peace of mind, we would stay with the Pfizer since we started out that way,” says Uniondale resident Joseph Ryan.
Others say if it is approved, it can help save lives.